We published that statins sensitize to venetoclax-mediated killing in CLL, AML, and B-cell lymphoma through a mechanism involving p53-independent upregulation of the p53 upregulated modulator of apoptosis (PUMA; ref. 25). Here, BBC3 is linked to B-cell non-Hodgkin lymphoma.